	US 12,310,959 B2
	Oral compositions with reduced water content
Anthony Richard Gerardi, Winston-Salem, NC (US); Dwayne William Beeson, Kernersville, NC (US); Ronald K. Hutchens, Advance, NC (US); Christopher Keller, Advance, NC (US); Thomas H. Poole, Winston-Salem, NC (US); Andries Don Sebastian, Winston-Salem, NC (US); and Frank Kelley St. Charles, Bowling Green, KY (US)
Assigned to Nicoventures Trading Limited, London (GB)
Filed by NICOVENTURES TRADING LIMITED, London (GB)
Filed on Dec. 9, 2019, as Appl. No. 16/707,637.
Prior Publication US 2021/0169868 A1, Jun. 10, 2021
Int. Cl. A61K 31/465 (2006.01); A24B 13/00 (2006.01); A24B 15/16 (2020.01); A24B 15/32 (2006.01); A61K 9/00 (2006.01); A61K 36/185 (2006.01); A61K 47/10 (2017.01)

CPC A61K 31/465 (2013.01) [A24B 13/00 (2013.01); A24B 15/16 (2013.01); A24B 15/32 (2013.01); A61K 9/0056 (2013.01); A61K 9/009 (2013.01); A61K 36/185 (2013.01); A61K 47/10 (2013.01)]

16 Claims

1. An oral composition comprising:

at least one releasable material;

at least one filler component comprising cellulose or a cellulose ether, the filler component present in an amount of about 50% to about 75% by weight; and

a polyol component comprising glycerin, propylene glycol, or a combination thereof, the polyol component present in an amount of about 25% by weight to about 40% by weight,

wherein the releasable material comprises an active ingredient selected from the group consisting of a nicotine component, a cannabinoid, and combinations thereof, the active ingredient present in an amount of 0.1-3% by weight, and

wherein the oral composition is in the form of a lozenge or pastille.